Bluetongue virus (BTV) is classified as a "transboundary animal disease" (TAD) and affects ruminants. TADs can spread rapidly across national borders. They have significant impacts on animal health. Now, the first vaccine against the disease is being launched:
- First vaccine that prevents clinical signs and mortality due to Bluetongue virus serotype 3 (BTV-3). Applicable to sheep and cattle.
- Following outbreaks of BTV-3 in the Netherlands, Belgium, and Germany, there is a risk of the disease spreading to neighboring countries.
- The use of the vaccine has been approved in Germany by the competent authority and will be available from early June 2024.
Boehringer Ingelheim is expanding its vaccine portfolio with an inactivated vaccine for sheep and cattle to combat Bluetongue virus (BTV). It is the first vaccine against BTV-3 that prevents mortality and clinical signs.
Furthermore, it reduces virus circulation in the animals' blood and thus the risk of further transmission of the disease. Boehringer Ingelheim, together with the company Bioveta, has succeeded in bringing this highly effective vaccine to market within just seven months.
